Investigating new HIV prevention methods and their effectiveness against acute infections
ACTION: Study of ACuTe Infections On Novel HIV Prevention Modalities
This study is looking at new ways to help prevent HIV, like a special vaginal ring and an injection, to see if they can make it easier for people to stay protected without having to take daily pills, especially for those in sub-Saharan Africa.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10849753 on NIH RePORTER |
What this research studies
This research focuses on improving HIV prevention strategies by evaluating new long-acting antiretroviral (ARV) options, such as the dapivirine vaginal ring and injectable cabotegravir. These methods aim to reduce reliance on daily medication adherence, which can be a barrier for many individuals. The study will assess the occurrence of acute HIV infections among users of these new prevention modalities and explore factors like ARV resistance that may impact their effectiveness. Participants may be involved in trials assessing how well these products work in real-world settings, particularly in sub-Saharan Africa.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for HIV who are considering or currently using PrEP methods.
Not a fit: Patients who are not at risk for HIV or those who are already on effective treatment regimens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV prevention methods that are easier for patients to use and adhere to.
How similar studies have performed: Previous research has shown promise in the effectiveness of long-acting PrEP methods, but this study aims to address specific challenges related to acute infections and drug resistance.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Koss, Catherine Anne Stimets — University of California, San Francisco
- Study coordinator: Koss, Catherine Anne Stimets
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.